New treatments outperforming placebo becoming less common

June 14, 2013
New treatments outperforming placebo becoming less common
The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

(HealthDay)—The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in BMJ, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine from 1966 to 2010.

The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).

"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.

Explore further: The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

Placebo often effective for treating headache in children

January 29, 2013

(HealthDay)—Placebo is often effective in treating children with headaches, and innovative strategies are needed to reduce the placebo response rate and prove drug effects in trials, according to two studies published online ...

Collagenase clostridium histolyticum OK in Peyronie's

April 26, 2013

(HealthDay)—For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal ...

Recommended for you

Bright lighting encourages healthy food choices

May 26, 2016

Dining in dimly lit restaurants has been linked to eating slowly and ultimately eating less than in brighter restaurants, but does lighting also impact how healthfully we order?

Big Data can save lives, says leading cancer expert

May 16, 2016

The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.

New soap to ward off malaria carrying mosquitoes

May 13, 2016

(Medical Xpress)—Gérard Niyondiko along with colleagues Frank Langevin and Lisa Barutel has posted a project on the crowd source funding site ulule for a product called Faso Soap. They claim the soap can cut in half the ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JRi
5 / 5 (1) Jun 15, 2013
Probably something to do with more strict guidelines, how tests need to be carried out nowadays. Laws require to inform authorities in advance when starting new tests. More difficult for pharmaceutical companies to "forget" the trials that failed to give positive outcome.
Wolf358
5 / 5 (1) Jun 15, 2013
Maybe it's all of the new improved extra-strength placebos....

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.